Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2019 Earnings Conference Call - Final Transcript
Nov 11, 2019 • 08:30 am ET
Good morning, ladies and gentlemen, and welcome to the Amicus Third Quarter 2019 Results Conference Call and Webcast. [Operator Instructions]
I would now like to turn the conference over to your host, Ms. Sara Pellegrino, Vice President of Investor Relations. You may begin.
Good morning. Thank you for joining our conference call to discuss Amicus Therapeutics' third quarter 2019 financial results and corporate highlights. Speaking on today's call we have John Crowley, Chairman and Chief Executive Officer; Bradley Campbell, President and Chief Operating Officer; and Daphne Quimi, Chief Financial Officer. Also joining for Q&A are Dr. Jay Barth, Chief Medical Officer; Dr. Hung Do, Chief Science Officer; and Dr. Jeff Castelli, Chief Portfolio Officer and Head of Gene Therapy.
As referenced on Slide 2, we may make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business as well as our plans and prospects. Our forward-looking statements should not be regarded as representation by us that any of our plans will be achieved. Any or all of the forward-looking statements made on this call may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. You are cautioned not to place undue reliance on any forward-looking statements, which speak only to the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this presentation and conference call to reflect events or circumstances after the date hereof.
For a full discussion of such forward-looking statements and the risks and uncertainties that may impact them, we refer you to the forward-looking statements and risk factors section of our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission. The third quarter press release and materials from today's call which will be corporate website and the quarterly report on 10-Q for the quarter ended September 30, 2019, to be filed following today's SEC holiday tomorrow.
At this time, it is my pleasure to turn the call over to John Crowley, Chairman and Chief Executive Officer of Amicus. John?
John F. Crowley
Great. Thanks, Sara and welcome everyone to our third quarter 2019 results conference call. I'm pleased to host today's conference call to highlight the tremendous effort and progress that we've made at Amicus during the third quarter and now into the early fourth quarter, beginning on Slide 3. A month ago at our Analyst Day in New York, we grounded everyone in the vision for what we are building the next great global biotechnology company poised to impact, many thousands of people around the world living with rare diseases.
To achieve this vision, we are continuing to grow our very successful Galafold base business which Brad will detail in a moment. We are also investing in the advancement of our leading rare disease pipeline including our Phase 3 Pompe biologic AT-GAA as well